Codagenix Completes Dosing in Phase 1 Trial of Universal Influenza Vaccine

Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced that it has completed dosing of its Phase 1 clinical trial to evaluate CodaVax™-H1N1, a universal, live-attenuated influenza vaccine. The randomized, double-blind clinical trial is being conducted in Australia and aims to assess the safety, tolerability and immunogenicity of the vaccine in healthy adults 18-49 years of age.